Kun‐Ming Rau

5.4k total citations
65 papers, 1.3k citations indexed

About

Kun‐Ming Rau is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Kun‐Ming Rau has authored 65 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 16 papers in Surgery. Recurrent topics in Kun‐Ming Rau's work include Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Gastric Cancer Management and Outcomes (9 papers) and Lung Cancer Treatments and Mutations (7 papers). Kun‐Ming Rau is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (13 papers), Gastric Cancer Management and Outcomes (9 papers) and Lung Cancer Treatments and Mutations (7 papers). Kun‐Ming Rau collaborates with scholars based in Taiwan, United States and South Korea. Kun‐Ming Rau's co-authors include Shau-Hsuan Li, Chien-Ting Liu, Yu‐Li Su, Yen‐Hao Chen, Tai‐Lin Huang, Yeh Tang, Yen‐Yang Chen, Victor C. Lin, Jia‐Ching Shieh and Pochuen Shieh and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Kun‐Ming Rau

64 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kun‐Ming Rau Taiwan	20	459	350	302	261	247	65	1.3k
Daniel Motola‐Kuba Mexico	17	481 1.0×	319 0.9×	218 0.7×	179 0.7×	230 0.9×	49	1.3k
Chun‐Shu Lin Taiwan	23	304 0.7×	371 1.1×	330 1.1×	374 1.4×	362 1.5×	87	1.4k
Davide Pastorelli Italy	19	496 1.1×	391 1.1×	298 1.0×	723 2.8×	458 1.9×	65	1.7k
Carmela Romano Italy	20	449 1.0×	307 0.9×	231 0.8×	113 0.4×	199 0.8×	76	1.5k
Ki Mun Kang South Korea	20	501 1.1×	413 1.2×	162 0.5×	288 1.1×	347 1.4×	71	1.4k
Keiichiro Nakamura Japan	28	606 1.3×	186 0.5×	495 1.6×	73 0.3×	251 1.0×	105	2.1k
Rudolf Morant Switzerland	17	1.1k 2.5×	465 1.3×	520 1.7×	287 1.1×	377 1.5×	36	1.8k
Ponnandai Somasundar United States	19	542 1.2×	264 0.8×	238 0.8×	225 0.9×	527 2.1×	77	1.8k
Hironori Hayashi Japan	22	442 1.0×	235 0.7×	305 1.0×	150 0.6×	341 1.4×	97	1.2k
Jane Koh Hong Kong	16	493 1.1×	232 0.7×	421 1.4×	849 3.3×	236 1.0×	31	1.7k

Countries citing papers authored by Kun‐Ming Rau

Since Specialization

Citations

This map shows the geographic impact of Kun‐Ming Rau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kun‐Ming Rau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kun‐Ming Rau more than expected).

Fields of papers citing papers by Kun‐Ming Rau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kun‐Ming Rau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kun‐Ming Rau. The network helps show where Kun‐Ming Rau may publish in the future.

Co-authorship network of co-authors of Kun‐Ming Rau

This figure shows the co-authorship network connecting the top 25 collaborators of Kun‐Ming Rau. A scholar is included among the top collaborators of Kun‐Ming Rau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kun‐Ming Rau. Kun‐Ming Rau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Daneng, Kun‐Ming Rau, Ming‐Lung Yu, et al.. (2025). Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, CHS-388) in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology. 43(4_suppl). 605–605. 1 indexed citations

Liu, Tsung‐Hao, San‐Chi Chen, Kun‐Ming Rau, et al.. (2024). Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression. Liver Cancer. 13(5). 509–521. 7 indexed citations

Tsai, Hui-Ju, Ju‐Chien Cheng, Yi‐Hsuan Chiang, et al.. (2021). Integrin αIIbβ3 outside-in signaling activates human platelets through serine 24 phosphorylation of Disabled-2. Cell & Bioscience. 11(1). 32–32. 4 indexed citations

Wu, Chia‐Che, Kun‐Ming Rau, Wei‐Chieh Lee, et al.. (2019). Presence of Chronic Obstructive Pulmonary Disease (COPD) Impair Survival in Lung Cancer Patients Receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI): A Nationwide, Population-Based Cohort Study. Journal of Clinical Medicine. 8(7). 1024–1024. 4 indexed citations

Huang, Pao‐Yuan, Chih‐Ming Liang, Wei‐Chen Tai, et al.. (2018). Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms. The Kaohsiung Journal of Medical Sciences. 34(11). 650–656. 16 indexed citations

Wang, Shih-Ho, et al.. (2017). Real world analysis of adjuvant chemotherapy for advanced gastric cancer after D2 radical surgery. Annals of Oncology. 28. iii36–iii37. 1 indexed citations

Su, Yu‐Li, Po‐Hui Chiang, Ming-Tse Sung, et al.. (2017). Novel Inflammation-Based Prognostic Score for Predicting Survival in Patients with Metastatic Urothelial Carcinoma. PLoS ONE. 12(1). e0169657–e0169657. 10 indexed citations

Wang, Shih-Ho, et al.. (2017). The effects of hospice-shared care for gastric cancer patients. PLoS ONE. 12(2). e0171365–e0171365. 13 indexed citations

Kuo, Yuan‐Hung, Jing‐Houng Wang, Chao‐Hung Hung, et al.. (2017). The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis. Investigational New Drugs. 36(2). 307–314. 29 indexed citations

10.

Chen, Yu‐Mu, Kun‐Ming Rau, Cheng-Hua Huang, et al.. (2016). Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer. 16(1). 868–868. 16 indexed citations

11.

Wang, Shih‐Hor, et al.. (2016). A Prognostic Model Using Inflammation- and Nutrition-Based Scores in Patients With Metastatic Gastric Adenocarcinoma Treated With Chemotherapy. Medicine. 95(17). e3504–e3504. 26 indexed citations

12.

Chen, Yu‐Mu, Kun‐Ming Rau, Cheng-Hua Huang, et al.. (2016). A Survival Scoring System for Non-Small Cell Lung Cancer Patients with De Novo Bone Metastases. PLoS ONE. 11(12). e0167923–e0167923. 3 indexed citations

13.

Lu, Yen‐Shen, Tom Wei‐Wu Chen, Ching‐Hung Lin, et al.. (2015). Bevacizumab Preconditioning Followed by Etoposide and Cisplatin Is Highly Effective in Treating Brain Metastases of Breast Cancer Progressing from Whole-Brain Radiotherapy. Clinical Cancer Research. 21(8). 1851–1858. 71 indexed citations

14.

Chiang, Po‐Hui, et al.. (2014). Metastatic Urothelial Carcinoma of the Bladder with Lymph Node-only Metastasis Treated with M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) has a Better Survival than GC (Gemcitabine and Cisplatin). SHILAP Revista de lepidopterología.

15.

Lim, Ho Yeong, Jeong Heo, Hye Jin Choi, et al.. (2014). A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma. Clinical Cancer Research. 20(23). 5976–5985. 86 indexed citations

16.

Ma, Ming‐Chun, Yen‐Yang Chen, Shau-Hsuan Li, et al.. (2014). Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma. The Scientific World JOURNAL. 2014. 1–8. 14 indexed citations

17.

Su, Yu‐Li, Yen‐Yang Chen, Hui‐Chun Chen, et al.. (2013). Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1–3 axillary lymph node(s) metastasis. Radiology and Oncology. 48(3). 314–322. 30 indexed citations

18.

Chiu, Tai‐Jan, Kun‐Ming Rau, Chang‐Han Chen, et al.. (2013). Midkine neurite growth-promoting factor 2 expression as a potential prognostic marker of adjuvant therapy in head and neck squamous cell carcinoma. Biomarkers. 18(8). 687–698. 10 indexed citations

19.

Rau, Kun‐Ming, Chao‐Cheng Huang, Tai‐Jan Chiu, et al.. (2012). Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers. Experimental and Therapeutic Medicine. 4(2). 231–236. 25 indexed citations

20.

Chen, Jen‐Shi, Jen‐Seng Huang, Tsai‐Shen Yang, et al.. (2004). Phase I dose escalation study of oxaliplatin combined with oral tegafur???uracil and leucovorin in patients with advanced gastric cancer. Anti-Cancer Drugs. 16(1). 47–51. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact